Answers are grounded in this paper and cite their sources.
Dear Editor, We read with interest White et al.’s analysis of hepatitis B virus (HBV) vaccine uptake among Ethiopian children aged 12–36 months. Their estimate of 51.2% complete coverage and its associations with maternal care and household resources offer useful evidence for immunization planning [1]. However, completion of the three-dose series cannot establish timely protection against perinatal HBV transmission. The authors classified children as completely vaccinated after three HBV doses. In Ethiopia’s 2016 routine programme, HBV was delivered in the pentavalent series at 6, 10, and 14 weeks; national introduction of a universal monovalent birth dose came later. Thus, the study’s endpoint measures completion of the routine infant series but not receipt of a birth dose within 24 hours. These outcomes address different clinical windows: the primary series protects against subsequent exposure, whereas timely birth-dose vaccination is central to preventing infection acquired around delivery. WHO recommends a birth dose for all infants as soon as possible after birth, preferably within 24 hours, followed by completion of the primary series [2, 3]. This distinction matters because perinatally infected infants have a high probability of developing chronic infection. A child could therefore be counted as ‘completely vaccinated’ while the analysis cannot establish whether the intervention most relevant to mother-to-child transmission was given on time. The association between maternal continuum-of-care use and dose completion is valuable, but without maternal HBsAg status, birth-dose timing, and linkage to newborn vaccination, it cannot show whether antenatal contact translated into prevention for exposed infants. The findings should therefore be interpreted as estimates of routine-series uptake, rather than comprehensive coverage of interventions preventing vertical transmission. Ethiopia launched national introduction of the HBV birth dose in November 2025, making this distinction especially relevant to current programme monitoring [4]. Future surveys should report HepB3 and timely birth-dose coverage separately, record the age at each dose, and, where feasible, link maternal HBsAg screening and positive results to newborn prophylaxis. Stratifying by place of birth could also identify missed opportunities for timely vaccination. Separating these indicators would preserve the value of the authors’ equity findings while preventing three-dose coverage from obscuring an early-life prevention gap. It would help decision-makers direct outreach towards infants who remain vulnerable to chronic infection acquired at birth. Ercan Yılmaz (Conceptualization [equal], Data Curation [equal], Formal Analysis [equal], Investigation [equal], Methodology [equal], Project administration [equal], Resources [equal], Software [equal], Supervision [equal], Validation [equal], Visualization [equal], Writing – original draft [equal], Writing – review & editing) [equal], and Erdem Topal (Conceptualization [equal], Formal Analysis [equal], Investigation [equal], Methodology [equal], Project administration [equal], Resources [equal], Software [equal], Supervision [equal], Validation [equal], Writing – original draft [equal], Writing – review & editing) The authors declare no conflict of interest. None. Research data are not shared. Not applicable. The authors used ChatGPT AI for language editing.
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: